J&J and Eli Lilly Concealed Breast Cancer Risks in Blockbuster Antipsychotics for Decades, Wisner Baum Lawsuit Alleges
Attorneys from Wisner Baum filed the complaint on behalf of plaintiff Bridgett Brown, who was prescribed both brand-name and generic versions of Risperdal and Zyprexa. She was diagnosed with breast cancer in approximately 2024.
This is the first lawsuit to allege that these antipsychotic drugs cause breast cancer. The complaint centers on the drugs' capacity to cause hyperprolactinemia—a hormonal imbalance directly tied to breast cancer development.
Recent studies cited in the lawsuit show significant increased breast cancer risks:
62% increased breast cancer risk for high-prolactin drugs like Risperdal and 54% increased risk for medium-prolactin drugs like Zyprexa – A study of 540,737 women (Rahman, 2023) 59% increased breast cancer risk for Risperdal – A review of 15 studies conducted on over 1 million individuals (Bird, 2025) 47% increased breast cancer risk after 5+ years of exposure to prolactin-increasing antipsychotics like Risperdal and Zyprexa – A Swedish registry study of 132,061 women (Solmi, 2024)
Atypical antipsychotic drugs were initially approved for treating severe schizophrenia. However, the lawsuit alleges the drug manufacturers broadened their customer bases by gaining approval for milder indications and promoting off-label use, including ADD in children and dementia in the elderly, generating billions in profits.
'These companies transformed narrow-use schizophrenia drugs into multi-billion-dollar per year blockbusters by targeting extremely vulnerable segments of our population, all while hiding a cancer risk they've known about for decades,' said Pedram Esfandiary, attorney for Ms. Brown.
The lawsuit alleges that despite knowledge dating back to the 1990s connecting these drugs to hyperprolactinemia, drug labels denied any cancer risk, stating until 2025, 'neither clinical trials nor epidemiological studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans.'
'The science has been clear on prolactin-elevating antipsychotics for decades,' said Monique Alarcon, attorney for Ms. Brown. 'These companies had a duty to inform; they failed, and now individuals nationwide are suffering the consequences. We intend to hold them accountable.'
The lawsuit seeks compensatory and punitive damages, alleging strict liability for failure to warn, negligence, and fraud. The case is Brown v. Johnson & Johnson et al (Case No. 25CV119808). Read the complaint here.
The award-winning law firm of Wisner Baum has successfully litigated cases against many of the largest pharmaceutical companies in the world. Since 1985, the firm has earned a reputation for breaking new legal ground, holding corporations accountable, influencing public policy, and raising public awareness on important safety issues. Using its longstanding tradition of success in the courtroom, the firm always strives to expose unsafe products or harmful practices to protect consumers from dangerous products. The firm has won over $4 billion in settlements and verdicts across all practice areas.
MEDIA CONTACTSteve Crighton, steve@newsroompr.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
an hour ago
- Malaysian Reserve
Parents Urged to Make Kids' Bedtime Screen-Free as National Campaign Launches with NYC Flash Mob
'Screen-Free Sleep' movement takes to the streets to address America's youth sleep crisis NEW YORK, Aug. 14, 2025 /PRNewswire/ — In a bold wake-up call to parents everywhere, the team behind the acclaimed Screenagers documentaries and the 'Away for the Day' campaign launched its latest national initiative on Tuesday, August 12th in NYC: Screen-Free Sleep, a movement to keep kids' bedrooms device-free at night and restore healthy rest to a generation in crisis. To mark the campaign's debut, New Yorkers were treated to an unexpected sight: an entire flash mob of Steve Jobs lookalikes – black turtlenecks, jeans, and all – took to the streets, handing out 'iSleep Pro' kits: sleek, phone-style packaging featuring simple sleep masks as a symbol of unplugged rest. Billed as a 'technological bedtime breakthrough,' the iSleep Pro kits unveiled the real game-changer: no devices in kids' bedrooms at night – a practice the campaign is calling the seatbelt of our time. The message was clear: parents must wake up to the growing crisis – with phones and screens invading bedtime, children are sleeping less, struggling more, and paying the price with their health, mood, and academic performance. 'Sleep is as essential to a child's health as nutrition and exercise,but right now, screens are robbing our kids of it,' said Dr. Delaney Ruston, physician, filmmaker, and co-founder of the Screen-Free Sleep campaign. 'Our campaign empowers parents to make bedrooms device-free at night, building habits that last through the teen years. By making screen-free sleep the norm, we can give our children the rest they need to thrive.' The Alarming Numbers: 1 in 4 tweens sleep with their phone in hand. Kids with devices in their bedroom are 2.3x more likely to feel tired during the day. 51% of teens get fewer than 7 hours of sleep most nights. The Solution: Parents are encouraged to take the pledge at to: Remove all devices – phones, tablets, laptops, smartwatches, gaming devices, even smart speakers – from kids' bedrooms at night. Provide a basic alarm clock to replace phone alarms. Store devices overnight in a secure location (ideally in a parent's bedroom to reduce temptation). Why It Matters: Research shows that simply having a device in the room, even if it's not in use, disrupts kids' sleep. Groundbreaking research shows that sleep deprivation in tweens is associated with MRI-verified disruptions in brain development. A device-free bedroom supports emotional regulation, attention, and school performance. How to Get Involved: Parents can sign the pledge, share the campaign with friends, and bring 'iSleep Pro' kits to schools, sports events, and community gatherings to help normalize screen-free sleep – just as seat belts became standard safety practice. Assets & Interviews Available: Flash Mob & Campaign Photos: HERE Available experts: Dr. Delaney Ruston – Physician, filmmaker, founder of Screenagers & Screen-Free Sleep Judith Owens, MD, MPH, expert in pediatric sleep medicine, Boston Children's Hospital Lauren Hale, Phd, Sleep Expert, Renaissance School of Medicine, NY Dr. Delaney Ruston – Physician, filmmaker, founder of Screenagers & Screen-Free Sleep Judith Owens, MD, MPH, expert in pediatric sleep medicine, Boston Children's Hospital Lauren Hale, Phd, Sleep Expert, Renaissance School of Medicine, NY To learn more, visit For additional details or to arrange interviews, please contact kelly@
Malaysian Reserve
8 hours ago
- Malaysian Reserve
GnRH Antagonists Market on Upward Trajectory During the Forecast Period (2025-2034) Across the 7MM
The GnRH inhibitor market is shifting toward more convenient, patient-focused treatments, driven by oral therapies such as ORGOVYX and YSELTY. As the pipeline continues to grow and indications expand, this drug class is poised for broader clinical use and is likely to play a key role in the future of hormonal suppression in oncology and women's health. LAS VEGAS, Aug. 13, 2025 /PRNewswire/ — DelveInsight's GnRH Receptor Antagonists Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Endometriosis, fibroids, prostate cancer, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging GnRH receptor antagonists, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the GnRH Receptor Antagonists Market Report As per DelveInsight's analysis, the total market size of GnRH receptor antagonists in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as Endometriosis, fibroids, prostate cancer, and others. Leading GnRH receptor antagonist companies, such as Debiopharm, Tiumbio, Antev, and others, are developing novel GnRH Receptor Antagonists that can be available in the GnRH receptor antagonist market in the coming years. Some of the key GnRH receptor antagonists in the pipeline include Debio 4326, Merigolix (TU2670), Teverelix, and others. In May 2025, TiumBio and Daewon Pharmaceutical completed Phase II clinical trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids with positive results. In March 2025, Kissei initiated the Phase III Clinical Trial for the GnRH Antagonist 'Linzagolix' indicated for Endometriosis in Japan. In February 2025, Kissei submitted New Drug Application (NDA) for 'linzagolix' indicated for Uterine Fibroids in Japan. In the EU, linzagolix received marketing authorization for uterine fibroids in June 2022. Discover which indication is expected to grab the major GnRH receptor antagonists market share @ GnRH Receptor Antagonists Market Report GnRH Receptor Antagonists Market Dynamics The GnRH receptor antagonists market is witnessing steady growth driven by advancements in therapeutic applications across a range of hormone-related disorders. These antagonists function by directly inhibiting GnRH receptors in the pituitary gland, thereby suppressing the release of LH and FSH. This mechanism provides a rapid and reversible suppression of sex hormones such as testosterone and estrogen, making them effective alternatives to GnRH agonists, which are associated with an initial hormone surge. Key indications for GnRH receptor antagonists include prostate cancer, endometriosis, uterine fibroids, and assisted reproductive technologies (ART). One of the significant drivers of market expansion is the growing prevalence of hormone-sensitive cancers, particularly prostate cancer in men and endometriosis or uterine fibroids in women. The increasing demand for therapies with improved safety profiles and faster onset of action has created a favorable environment for GnRH antagonists. Moreover, recent product launches such as RELUGOLIX (marketed as ORGOVYX for prostate cancer and MYFEMBREE for uterine fibroids) and ELAGOLIX (marketed as ORILISSA for endometriosis and ORIAHNN for fibroids) have gained regulatory approvals and demonstrated commercial success, further validating the therapeutic potential of this class. Additionally, the market is benefiting from a broader shift towards oral therapies. Unlike older GnRH agonists, many of the newer antagonists are available in oral formulations, improving patient adherence and convenience. This factor is particularly significant in chronic indications where long-term management is necessary. The preference for non-invasive treatment options among patients and providers is reshaping treatment paradigms and expanding the reach of GnRH antagonists beyond hospital settings to outpatient care. However, the market also faces certain challenges. Cost of therapy remains a barrier in several regions, particularly in low- and middle-income countries, where access to advanced hormonal therapies is limited. Furthermore, competition from alternative treatment modalities such as aromatase inhibitors, progestins, and surgical interventions can restrict market penetration in some indications. Intellectual property protection, regulatory requirements, and long development timelines can also impact new entrants and biosimilar competition. In the coming years, continued R&D in expanding the therapeutic use of GnRH antagonists, including potential applications in breast cancer, male infertility, and transgender hormone therapy, is likely to support further market growth. Strategic collaborations, licensing deals, and increasing investments by pharmaceutical companies in reproductive health and oncology are expected to drive innovation and market competitiveness. Overall, the GnRH receptor antagonists market is positioned for sustained growth, underpinned by clinical efficacy, patient-centric delivery formats, and expanding disease awareness. GnRH Receptor Antagonists Treatment Market The introduction of oral GnRH antagonists, known for their rapid onset of action, is reshaping treatment approaches for several prevalent gynecologic and oncologic conditions such as endometriosis, uterine fibroids, and prostate cancer. Over the past decade, the GnRH inhibitor market has undergone a significant transformation, moving from injectable formulations to more convenient oral therapies. Initially, the market was led by FIRMAGON, an injectable GnRH antagonist approved in 2008 for advanced prostate cancer. However, a major turning point came in 2020 with the approval of ORGOVYX by Sumitomo Pharma—the first oral GnRH antagonist for prostate cancer. ORGOVYX marked a clinical advancement by eliminating the testosterone flare linked with GnRH agonists and improving patient convenience by removing the need for injections. Its rapid adoption in androgen deprivation therapy (ADT) highlighted a growing preference for oral options. Another significant development was the approval of YSELTY (linzagolix) in 2022 by the EMA for treating uterine fibroids and endometriosis. Developed by Theramex and Kissei, YSELTY extended the use of GnRH antagonists into women's health, offering a once-daily oral therapy with customizable suppression levels to help mitigate long-term estrogen deficiency effects. This approval further validated the use of oral GnRH inhibitors beyond oncology and underscored their expanding role in broader therapeutic areas. Learn more about the GnRH receptor antagonists @ GnRH Receptor Antagonists Analysis Key Emerging GnRH Receptor Antagonists and Companies Key players in the GnRH receptor antagonist market include Tiumbio (Merigolix), Antev (Teverelix), Debiopharm (Debio 4326), and others. Debio 4326 is an innovative, injectable, and biodegradable formulation of triptorelin, designed to provide extended-release over 12 months for managing central precocious puberty (CPP). Its key advantage lies in significantly reducing injection frequency, thereby easing the treatment experience for children with this rare condition. Developed based on positive efficacy and safety data from existing 1-, 3-, and 6-month triptorelin products, this new version aims to enhance long-term adherence and minimize the emotional and physical stress on both children and their caregivers. Debio 4326 is currently undergoing a Phase 3 clinical trial across North and South America to assess its efficacy and safety. Teverelix is a long-acting, injectable GnRH antagonist formulated using a novel microcrystal technology that addresses the known safety limitations of earlier GnRH antagonist treatments for prostate cancer. With favorable injection site tolerance and a six-week dosing schedule, Teverelix is positioned to offer better patient compliance and improved treatment outcomes. Beyond prostate cancer, it also holds potential for treating benign prostate hyperplasia (BPH), acute urinary retention (AUR), endometriosis, and uterine fibroids. In January 2023, the U.S. FDA reviewed early-stage clinical data (Phase I and IIa) and provided written feedback on the design of Antev's planned Phase III trial for Teverelix, targeting patients with advanced prostate cancer and high cardiovascular risk—an area with significant unmet clinical need. Subsequently, in December 2023, the FDA approved a Phase IIb trial involving 40 patients with advanced prostate cancer. In November 2024, the agency also approved another Phase IIb study for acute urinary retention, set to enroll 390 patients. These regulatory milestones support Antev's broader strategy to advance Teverelix as a targeted therapy for patients with specific medical needs. The anticipated launch of these emerging therapies are poised to transform the GnRH receptor antagonists market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the GnRH receptor antagonists market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about GnRH receptor antagonists clinical trials, visit @ GnRH Receptor Antagonists Treatment GnRH Receptor Antagonists Overview GnRH antagonists mark a notable improvement in androgen deprivation therapy (ADT) for treating hormone-sensitive prostate cancer. These drugs function by directly inhibiting GnRH receptors in the pituitary gland, which quickly suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a rapid drop in testosterone levels. This direct mechanism avoids the initial testosterone surge, or 'flare', that is often seen with other forms of ADT. A major clinical benefit of GnRH antagonists is their swift action, with testosterone levels typically reaching castration thresholds within days. This rapid hormonal suppression is especially beneficial for patients with metastatic or symptomatic disease who require immediate control. Moreover, GnRH antagonists have shown better cardiovascular safety compared to traditional treatments. For instance, the HERO trial demonstrated that relugolix, a once-daily oral GnRH antagonist, significantly reduced the risk of major cardiovascular events. As a result, these agents are particularly advantageous for patients with existing heart-related conditions. GnRH Receptor Antagonists Epidemiology Segmentation The GnRH receptor antagonists market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for GnRH Receptor Antagonist Total Eligible Patient Pool for GnRH Receptor Antagonist in Selected Indications Total Treated Cases in Selected Indications for GnRH Receptor Antagonist GnRH Receptor Antagonists Report Metrics Details Study Period 2020–2034 GnRH Receptor Antagonists Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report Endometriosis, fibroids, prostate cancer, and others Key GnRH Receptor Antagonist Companies Debiopharm, Tiumbio, Antev, Ferring Pharmaceuticals, Sumitomo Pharma, Theramex, Kissei, and others Key GnRH Receptor Antagonists Debio 4326, Merigolix (TU2670), Teverelix, FIRMAGON, ORGOVYX, YSELTY, and others Scope of the GnRH Receptor Antagonists Market Report GnRH Receptor Antagonists Therapeutic Assessment: GnRH Receptor Antagonists' current marketed and emerging therapies GnRH Receptor Antagonists Market Dynamics: Conjoint Analysis of Emerging GnRH Receptor Antagonists Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, GnRH Receptor Antagonists Market Access and Reimbursement Discover more about GnRH receptor antagonists in development @ GnRH Receptor Antagonists Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary of GnRH Receptor Antagonist 4 Key Events 5 Epidemiology and Market Forecast Methodology 6 GnRH Receptor Antagonist Market Overview at a Glance in the 7MM 6.1 Market Share (%) Distribution by Therapies in 2024 6.2 Market Share (%) Distribution by Therapies in 2034 6.3 Market Share (%) Distribution by Indications in 2024 6. Market Share (%) Distribution by Indications in 2034 7 GnRH Receptor Antagonist: Background and Overview 7.1 Introduction 7.2 Treatment 8 Target Patient Pool 8.1 Key Findings 8.2 Assumptions and Rationale: 7MM 8.3 Epidemiology Scenario in the 7MM 8.4 Total Cases in Selected Indications for GnRH Receptor Antagonist in the 7MM 8.5 Total Eligible Patient Pool for GnRH receptor antagonist in Selected Indications in the 7MM 8.6 Total Treated Cases in Selected Indications for GnRH Receptor Antagonist in the 7MM 9 Marketed Therapies 9.1 Key Competitors 9.2 FIRMAGON (degarelix): FERRING PHARMACEUTICALS 9.2.1 Product Description 9.2.2 Regulatory milestones 9.2.3 Other developmental activities 9.2.4 Clinical development 9.2.5 Safety and efficacy 9.3 ORGOVYX (relugolix): Sumitomo Pharma List to be continued in the report 10 Emerging Therapies 10.1 Key Competitors 10.2 Debio 4326: Debiopharm 10.2.1 Product Description 10.2.2 Other developmental activities 10.2.3 Clinical development 10.2.4 Safety and efficacy 10.2.5 Analyst Views 10.3 Teverelix: Antev List to be continued in the report 11 GnRH Receptor Antagonist: Seven Major Market Analysis 11.1 Key Findings 11.2 Market Outlook 11.3 Conjoint Analysis 11.4 Key Market Forecast Assumptions 11.4.1 Cost Assumptions and Rebates 11.4.2 Pricing Trends 11.4.3 Analogue Assessment 11.4.4 Launch Year and Therapy Uptakes 11.5 Total Market Size of GnRH receptor antagonist in the 7MM 11.6 Market Size of GnRH Receptor Antagonist by Indication in the 7MM 11.7 Market Size of GnRH Receptor Antagonist by Therapies in the 7MM 11.8. The United States Market Size 11.8.1 Total Market Size of GnRH Receptor Antagonists in the United States 11.8.2 Market Size of GnRH Receptor Antagonist by Therapies in the United States 11.9 EU4 and the UK Market Size 11.10 Japan Market Size 12 Market Access and Reimbursement 13 SWOT Analysis of GnRH Receptor 14 KOL Views of GnRH Receptor 15 Unmet Needs of GnRH Receptor 16 Bibliography 17 Report Methodology Related Reports Prostate Cancer Market Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer companies, including Sanofi, AstraZeneca, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, among others. Prostate Cancer Pipeline Prostate Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key prostate cancer companies, including Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen Biopharmaceuticals, LAVA Therapeutics, Essa Pharma, Poseida Therapeutics, Janux Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, AbbVie, SL VAXiGEN, Sorrento Therapeutics, Inc., 858 Therapeutics, Avacta Life Sciences Ltd, Nammi Therapeutics, BeiGene, DualityBio, among others. Endometriosis Market Endometriosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis companies, including Mitsubishi Tanabe Pharma America, Ferring Pharmaceuticals, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Organon, among others. Uterine Fibroids Market Uterine Fibroids Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key uterine fibroids companies, including AbbVie Inc., Addex Therapeutics Ltd, Bayer AG, BioSpecifics Technologies Corp, Dongkook Pharmaceutical Co Ltd, Kissei Pharmaceutical Co Ltd, Myovant Sciences, Ogeda SA, Repros Therapeutics Inc., Takeda Pharmaceutical Company Ltd, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content:
Malaysian Reserve
12 hours ago
- Malaysian Reserve
Elevating Clinical Excellence: TLCx Appoints Dr Ries as Chief Medical Officer
CEDAR RAPIDS, Iowa, Aug. 13, 2025 /PRNewswire/ — TLCx is taking a significant step toward its long-term vision of transforming the healthcare patient experience. This move underscores the company's dedication to pioneering a new era of healthcare, one rooted in thoughtful design, patient-centered systems, and clinically sound innovation. 'This is more than just a clinical appointment; it signifies a key milestone in realizing TLCx's Vision 2030,' said Dr. Zachary Ries, Chief Medical Officer. 'It will pioneer a new era of healthcare patient experience driven by intelligent design, human-first systems, and clinically grounded innovation.' TLCx is pleased to welcome Dr. Zachary Ries as its first Chief Medical Officer. This decisive appointment highlights TLCx's dedication to reshaping the patient experience through clinically grounded innovation and human-first systems. Dr. Ries's expertise will be instrumental in guiding TLCx toward its Vision 2030, which focuses on creating a healthcare journey prioritizing the needs and well-being of patients. Tom Cardella, Founder and CEO of TLCx, added, 'I've known Dr. Ries for many years, and I couldn't be more excited to have him join TLCx, especially at this time of transformation through human-driven AI solutions. His expertise and vision will be pivotal as we redefine healthcare delivery.' Dr. Zachary Ries is a Board-Certified Orthopedic Spine Surgeon from Des Moines, Iowa, with nearly 18 years of medical experience. A University of Iowa graduate with advanced fellowship training at Norton Leatherman Spine Center, he is dedicated to improving patient care through clinical expertise and innovation. The addition of a Chief Medical Officer will benefit the company in the following ways: Enhanced Clinical Leadership: Dr. Ries will provide vital leadership, ensuring TLCx's strategies and innovations are firmly rooted in medical expertise. Patient-Centered Approach: With Dr. Ries at the helm, TLCx will further emphasize a patient-centered approach, designing systems and experiences that address the unique needs of each individual. Realization of Vision 2030: This appointment marks a milestone in realizing TLCx's Vision 2030, moving the company closer to its goal of transforming healthcare patient experience. Drive Innovation: Dr. Ries will also help drive innovation at TLCx, leading development of products, services, and solutions that improve patient experience and outcomes. About TLCx:TLCx is a certified veteran-owned company dedicated to enhancing customer experiences for Fortune 500 companies through innovative outsourcing solutions. With a focus on operational excellence and a people-first culture, TLCx has been a trusted partner in the CX industry for 18 years. For more information, visit Media Contact:Bryan GrayChief Commercial
